We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $88.17 · 12 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results - simplywall.st
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results simplywall.st
Arrowhead Pharmaceuticals (ARWR) Reveals Promising Interim Trial Results - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Reveals Promising Interim Trial Results GuruFocus
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - Business Wire
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 Business Wire
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-1.2 | — | — | $46.68M | — | Scheduled |
| FY2026 Q2 | 2025. 03. 31. | Time TBD | — | $1.52 | — | — | $545.21M | Reported |
| FY2026 Q1 | 2024. 12. 31. | Time TBD | — | $-1.39 | — | — | $2.5M | Reported |
| FY2025 Q3 | 2024. 06. 30. | Time TBD | — | $-3.63 | — | — | $3.55M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Bernstein | — | Maintain | Market Perform → Market Perform | — | Bernstein: Market Perform |
| 2026. 05. 09. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 01. | JP Morgan | — | Initiate coverage | — → Overweight | — | JP Morgan: Overweight |
| 2026. 04. 21. | Morgan Stanley | — | Upgrade | Equal-Weight → Overweight | — | Morgan Stanley: Equal-Weight → Overweight |
| 2026. 03. 26. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 02. 10. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q2 · Source: SEC/DART + price data
No holdings data to show.